Coherus Oncology, Inc. (CHRS) by event type
CHRS moves most on analyst downgrades — a median of -1.71% at 30 minutes across 13 measured events. Each row is measured over the last three years and read against the price at its own news timestamp. Back to the CHRS overview →
How CHRS reacts across 4 measured event types.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades 2,523 of 2,717 | 12 | -0.76% | 25% | -1.50% |
| Analyst downgrades 2,509 of 2,603 | 13 | -1.71% | 23% | -10.18% |
| Coverage initiations 140 of 2,283 | 10 | +1.06% | 100% | +11.35% |
| Rating reiterations 133 of 3,522 | 42 | +0.56% | 52% | -0.50% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The rank under each event type orders every name measured for it by median 30-min reaction, most positive first — so a low rank on a downgrade means this name falls harder than most, not that it moves less. Names with an identical median share a rank; a name the cross-section does not carry shows no rank rather than a guessed one. 2 further classes were observed with fewer than 10 measured events and are not published.
That’s how CHRS usually reacts — get an email when it moves on news →Every name measured for these event types: Analyst upgrades → · Analyst downgrades → · Coverage initiations → · Rating reiterations → · CHRS overview →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Can-Fite Biopharma Ltd American Depositary Shares, each representing two (2) Ordinary Shares (CANF) | 278 | -0.48% | 36% |
| AtriCure, Inc. (ATRC) | 276 | +0.04% | 51% |
| Xenon Pharmaceuticals Inc. - Common Shares (XENE) | 276 | +0.03% | 50% |
| Aclaris Therapeutics, Inc. (ACRS) | 275 | 0.00% | 48% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.